Physician profile
Kevin Fu
NPI 1376938167
$14,011.66
in general payments reported to CMS, 2019-2025
36 companies · $1,740 in 2025
The $1,740 reported for 2025 was more than what 88% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.59 · 2020: $685 · 2021: $2,883 · 2022: $2,393 · 2023: $3,520 · 2024: $2,697 · 2025: $1,740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,386 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500 · Education: $70.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,385.67 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
| Education | $70.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,052.86 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $1,901.99 | 2020-2025 | Tavneos, Krystexxa, Parsabiv |
| Daiichi Sankyo INC. | $966.32 | 2020-2023 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $953.62 | 2021-2025 | |
| Baxter Healthcare | $873.03 | 2022-2024 | Renal - Acute, Renal - Prismax System, Renal - Pd |
| Opko Pharmaceuticals, LLC | $650.02 | 2020-2024 | Rayaldee |
| Aurinia Pharma U.S., INC. | $569.19 | 2021-2024 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $507.09 | 2020-2025 | Jynarque, Voyxact |
| Novartis Pharmaceuticals Corporation | $464.20 | 2023-2025 | |
| Vifor Pharma, INC. | $372.43 | 2020-2025 | Veltassa |
| Horizon Therapeutics Plc | $347.12 | 2022-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $277.11 | 2023-2025 | Jardiance |
| Travere Therapeutics, INC. | $266.99 | 2022-2025 | Filspari |
| Novo Nordisk INC | $253.50 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $247.70 | 2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $238.23 | 2021-2025 | Benlysta |
| Calliditas Therapeutics US INC. | $235.93 | 2022-2025 | Tarpeyo |
| Bard Peripheral Vascular, INC. | $211.33 | 2021-2022 | |
| Vantive US Healthcare LLC | $211.16 | 2025 | Renal - Pd, Renal - Acute |
| Mallinckrodt Hospital Products INC. | $198.47 | 2020-2025 | Terlivaz |
| Pharmacosmos Therapeutics INC. | $178.89 | 2021-2025 | Monoferric |
| Cormedix INC. | $178.88 | 2024-2025 | Defencath |
| Becton, Dickinson and Company | $142.48 | 2023 | |
| Alexion Pharmaceuticals, INC. | $112.05 | 2021-2024 | Ultomiris |
| Akebia Therapeutics INC | $109.82 | 2020-2022 | |
| Ani Pharmaceuticals, INC. | $94.85 | 2022-2025 | Purified Cortrophin Gel |
| Ardelyx, INC. | $93.28 | 2023-2025 | Ibsrela |
| Veloxis Pharmaceuticals, INC. | $77.33 | 2020-2022 | |
| Scpharmaceuticals INC. | $50.91 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $43.85 | 2021-2023 | |
| Nuwellis, INC. | $28.65 | 2020 | |
| Alnylam Pharmaceuticals INC. | $25.21 | 2022 | |
| Corium, LLC | $24.47 | 2023 | Adlarity |
| Abbott Laboratories | $21.97 | 2025 | Cardiomems |
| Apellis Pharmaceuticals, INC. | $18.43 | 2025 | |
| Nxstage Medical, INC. | $12.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Fu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.